Richard Bagley
Präsident bei Samus Therapeutics, Inc.
Profil
Richard E.
Bagley currently works at Samus Therapeutics, Inc., as President from 2016.
Mr. Bagley also formerly worked at ImmuLogic Pharmaceutical Corp., as President & Chief Executive Officer from 1990 to 1994, Twin Butte Energy Ltd., as President & Chief Executive Officer from 1998 to 2003, ProScript, Inc., as Chairman & Chief Executive Officer from 1994 to 1998, Alaunos Therapeutics, Inc., as President, Chief Operating Officer & Director in 2012, ZIOPHARM, Inc., as President & Chief Operating Officer from 2004 to 2005, Smithkline & French Laboratories US, Inc., as President-Over-The-Counter & Consumer Group from 1968 to 1985, and E.
R.
Squibb & Sons LLC, as President from 1988 to 1989.
Mr. Bagley received his graduate degree from Harvard Graduate School of Education.
Aktive Positionen von Richard Bagley
| Unternehmen | Position | Beginn |
|---|---|---|
Samus Therapeutics, Inc.
 Samus Therapeutics, Inc. BiotechnologyHealth Technology Samus Therapeutics, Inc. operates as an biopharmaceutical company. It develops novel therapeutics targeting the epichaperome to enhance degradation of aberrant proteins which drive the pathology of diseases such as neurodegenerative and cancer. The company is headquartered in Topsfield, MA. | Präsident | 01.11.2016 |
Ehemalige bekannte Positionen von Richard Bagley
| Unternehmen | Position | Ende |
|---|---|---|
| ALAUNOS THERAPEUTICS, INC. | Finanzdirektor/CFO | 09.05.2012 |
| ZIOPHARM, Inc. | Präsident | 01.09.2005 |
| TWIN BUTTE ENERGY LTD. | Präsident | 01.05.2003 |
ProScript, Inc.
 ProScript, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., ProScript, Inc. is a company that develops anti-cancer treatments. The company is based in Cambridge, MA. The company was founded by Tom Maniatis. ProScript was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on July 20, 1999 for $3.35 million. | Vorsitzender | 01.01.1998 |
ImmuLogic Pharmaceutical Corp.
 ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN. | Präsident | 01.01.1994 |
Ausbildung von Richard Bagley
| Harvard Graduate School of Education | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| TWIN BUTTE ENERGY LTD. | Energy Minerals |
| ALAUNOS THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
ImmuLogic Pharmaceutical Corp.
ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN. | Health Technology |
| ZIOPHARM, Inc. | Health Technology |
ProScript, Inc.
ProScript, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., ProScript, Inc. is a company that develops anti-cancer treatments. The company is based in Cambridge, MA. The company was founded by Tom Maniatis. ProScript was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on July 20, 1999 for $3.35 million. | Health Technology |
| Smithkline & French Laboratories US, Inc. | |
| E. R. Squibb & Sons LLC | |
Samus Therapeutics, Inc.
Samus Therapeutics, Inc. BiotechnologyHealth Technology Samus Therapeutics, Inc. operates as an biopharmaceutical company. It develops novel therapeutics targeting the epichaperome to enhance degradation of aberrant proteins which drive the pathology of diseases such as neurodegenerative and cancer. The company is headquartered in Topsfield, MA. | Health Technology |
